Home / Stock ratings / Healthcare Stocks / DHR
Stock rating · Industrial Instruments for Measurement, Display, and Control
Danaher Corporation (DHR) Stock Rating & Analysis
As of November 20, 2026, MELANY rates Danaher Corporation 63 out of 100 (Hold). Its highest factor score is earnings track record at 81, and its lowest is catalyst setup at 47.
DHR · composite score
About Danaher Corporation
Danaher's founders converted a real estate organization into an industrial manufacturer in 1984 and reshaped the company over time through mergers, acquisitions, and divestitures. Following the late-2023 spin-off of its environmental and applied solutions group, Veralto, Danaher now concentrates mainly on making scientific instruments and consumables for the life sciences and diagnostics industries.
Rating as of 2026-11-20 · this is a dated snapshot; the live rating and the live price are in the app (the rating is part of Pro, free for 30 days).
Why DHR scores 63/100
DHR's 8 factor scores run from 47 to 81, and 3 of them sit above its composite of 63. Here is how DHR breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
- Forward P/E 23.6x, earnings growth accelerating
Margins, returns on capital, and balance-sheet strength.
- Gross margin 59%
Direction and relative strength of the recent share-price trend.
- 50-day MA above 200-day (golden cross zone)
History of beating or missing estimates, and where estimates are heading.
- Beat EPS estimates 4 of last 4 quarters
- Avg EPS beat +5%
What Wall Street price targets and revisions are signalling.
Near-term events that could move the stock.
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
How DHR compares
As of November 20, 2026, Danaher Corporation is tied for 8th of 20 in Healthcare Stocks, where the average score is 62.
Key risks for DHR
- Performance partly driven by Healthcare sector, rotation away from this theme would hurt
Sector and theme context
Danaher Corporation sits in the Healthcare sector theme, which MELANY currently rates 99/100 for strength. Theme strength feeds DHR's momentum and catalyst factors above.
Tracking DHR
Danaher Corporation rates Hold right now, so MELANY is not flagging a fresh entry. Add DHR to a watchlist in the app to follow its rating; an alert the moment it changes is part of Pro, free for 30 days.
How MELANY rates DHR
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Danaher Corporation's 63/100 reflects mature factor weighting for its profile.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about DHR
Is Danaher Corporation (DHR) a buy?
As of 2026-11-20, MELANY rated Danaher Corporation Hold with a composite score of 63/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
How does DHR rank against similar companies?
As of November 20, 2026, Danaher Corporation is tied for 8th of 20 in MELANY's Healthcare Stocks list, where the average score is 62. Among the other names in the list, the highest scores belong to REGN (74) and MDT (71).
Should I buy Danaher Corporation stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Danaher Corporation (DHR) Hold with a composite of 63/100 as of 2026-11-20. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the DHR stock price forecast?
MELANY does not publish price targets or forecasts for DHR. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 63/100 across eight factors for Danaher Corporation, and re-scores automatically as new price, earnings, and fundamental data arrive. What it does read for DHR as of 2026-11-20: its analyst sentiment factor is 75/100, and its price momentum factor is 63/100.
Is DHR stock overvalued or undervalued?
MELANY's valuation factor currently reads 49/100 for Danaher Corporation, where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives DHR's read.
What price should I buy DHR at?
MELANY is not flagging a fresh entry for DHR at its current Hold rating, so there is no entry zone to publish right now. Add DHR to a watchlist in the app to follow it; an alert the moment the rating changes is part of Pro, free for 30 days.
What are the risks of buying DHR stock?
The top risks MELANY currently flags for Danaher Corporation: Performance partly driven by Healthcare sector, rotation away from this theme would hurt. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Danaher Corporation a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 63/100 for Danaher Corporation, and earnings track record, at 81/100. The 63/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will DHR stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 63/100 for DHR right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this DHR rating?
The rating on this page is a snapshot of MELANY's read as of 2026-11-20, and the score is not recomputed on this page. MELANY re-scores DHR as new price, earnings, and fundamental data arrive; the current rating and the live price are in the app (the rating is part of Pro, free for 30 days).
How this rating works
Market Eyes Live
Every rating graded in public, DHR included
MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.